Analysis of Pooled Data from Phase 3 Trial Results Show Glycaemic Efficacy of INVOKANAÂ® (canagliflozin) is Largely Independent of Beta-Cell Function and Insulin Sensitivity in the Treatment of Type 2 Diabetes in Adults